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Objectives. Research has indicated that there is minimal use of pharmacies
among injection drug users (IDUs) in specific neighborhoods and among Black
and Hispanic IDUs. We developed a community-based participatory research
partnership to determine whether a multilevel intervention would increase ster-
ile syringe access through a new policy allowing nonprescription syringe sales
in pharmacies. 
Methods. We targeted Harlem, NY (using the South Bronx for comparison),
and disseminated informational material at community forums, pharmacist train-
ing programs, and counseling or outreach programs for IDUs. We compared
cross-sectional samples in 3 target populations (pre- and postintervention): com-
munity members (attitudes and opinions), pharmacists (opinions and practices),
and IDUs (risk behaviors).
Results. Among community members (N = 1496) and pharmacists (N = 131),
negative opinions of IDU syringe sales decreased in Harlem whereas there was
either no change or an increase in negative opinions in the comparison com-
munity. Although pharmacy use by IDUs (N=728) increased in both communities,
pharmacy use increased significantly among Black IDUs in Harlem, but not in
the comparison community; syringe reuse significantly decreased in Harlem, but
not in the comparison community.
Conclusions. Targeting the individual and the social environment through a
multilevel community-based intervention reduced high-risk behavior, particu-
larly among Black IDUs. (Am J Public Health. 2007;97:117–124. doi:10.2105/
AJPH.2005.069591)
group to address this issue. The partnership
had been formed 2 years earlier, as de-
scribed elsewhere,16 and currently includes
30 community-based organizations in
Harlem, 4 academic institutions, and the
local health department. Because of the com-
plex social factors (e.g., police harassment,
various types of discrimination) that con-
tribute to injection risk, and previous work
that shows how contextual factors (e.g., pub-
lic policy, cultural norms, illegality of drug
use) may influence individual behaviors, a
multilevel design was chosen.17–19 Using a
community-based participatory research ap-
proach,20 we targeted 3 populations: commu-
nity residents, pharmacists, and IDUs. The
specific goals for the intervention were (1) to
sensitize community residents to drug users
and dispel negative myths by providing edu-
cation on the positive affect that ESAP could
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have in their community (e.g., reducing the
risk and burden of HIV disease), (2) to pro-
vide education to pharmacists about what
was and was not required by the law and
provide information to help dispel negative
perceptions of drug users, and (3) to increase
awareness of ESAP among IDUs and provide
the location and hours of ESAP-participating
pharmacies and information about safe injec-
tion and syringe disposal practices. All activi-
ties were to be performed in a culturally ap-
propriate manner to specifically reach Black
and Hispanic IDUs.
We report the final results of our non-
randomized, multilevel intervention, includ-
ing pre- and postintervention evaluations
in both intervention (Harlem) and compari-
son (South Bronx) communities. Using a
community-based participatory research
approach, we obtained data on 3 target
The many strategies for preventing HIV/
AIDS among injection drug users (IDUs)
who cannot cease drug use have included
syringe exchange programs and the removal
of barriers to purchase (primarily through
pharmacies) and possess syringes.1 Syringe
exchange programs, which couple syringe
exchange with counseling, education, and re-
ferrals to care, have been shown to reduce
HIV infection. However, obstacles such as
fear of being identified as an IDU and police
harassment have prevented some IDUs from
using these programs.2–7 Furthermore, inad-
equate syringe supplies, limited operation
hours, and long travel distances have also
been identified as barriers to syringe ex-
change program use.8,9 As a result, numer-
ous researchers urge the use of pharmacies
as safe syringe sources to supplement sy-
ringe exchange programs.1,10
Recognizing this need, New York State en-
acted the Expanded Syringe Access Demon-
stration Program (ESAP), which permits phar-
macy syringe sales without a prescription.
Since January 1, 2001, individuals aged 18
years or older have been permitted to pur-
chase and legally possess up to 10 syringes
without a prescription from pharmacies regis-
tered with the New York State Department of
Health. Early data revealed that IDUs in East
and Central Harlem (referred to as “Harlem”
hereafter) and South Bronx minimally partici-
pated in ESAP.11–14 In addition, studies indi-
cated that Black and Hispanic drug users
were less likely to use pharmacies as safe and
legal syringe sources compared with their
White counterparts, irrespective of geo-
graphic location.11,12,14,15
In the summer of 2001, the Harlem Com-
munity and Academic Partnership recognized
the disparities in both the use of ESAP and
the burden of HIV disease in their commu-
nity, and organized an intervention work
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Community residents, pharmacists, and
IDUs were sampled at 2 time points: prein-
tervention and postintervention. Community
residents were drawn from randomly se-
lected households on the basis of geographic
eligibility (identified by the nearest major in-
tersection) in each of 2 locations in New
York: Harlem (intervention) and South Bronx
(comparison). Further randomization of
adults within the household was performed
by selecting the individual aged 18 years or
older who reported a birth date closest to the
call date. The final community sample size
was 742 residents preintervention (interven-
tion=494; comparison=248) and 754 resi-
dents postintervention (intervention=505;
comparison=249).
Pharmacies were selected from a database
of listings from the New York State Depart-
ment of Health combined with listings ob-
tained from Yellowpages.com (http://www.
yellowpages.com), an online directory col-
lected from phone books and new business
listings. Because of the modest number of
pharmacies registered in South Bronx, the
Bedford-Stuyvesant community in Brooklyn
(with similar demographics) was added to the
comparison community, which yielded 106
pharmacies in the comparison community
and 45 in the intervention community. Phar-
macies were excluded from the study if their
phone was disconnected, if they did not pro-
vide over-the-counter services, or if the super-
vising pharmacist was unwilling to participate.
Pharmacists were only called when customer
volume was expected to be low (on the basis
of pilot testing). In the intervention commu-
nity, 53% (n=24) of the pharmacists partici-
pated in the preintervention phone survey
and 62% (n=28) participated in the postin-
tervention survey. In the comparison commu-
nity, 44% (n=47) and 31% (n=33) partici-
pated in the pre- and postintervention
surveys, respectively. Although it is likely that
some pharmacists surveyed preintervention
were the same pharmacists surveyed post-
intervention, confidentiality issues prevented
linking these individuals at these 2 time
points.
To enhance feasibility and efficiency of
this study, 2 preexisting IDU studies that
used similar recruitment techniques provided
the samples for pre- and postintervention
periods. IDUs for both studies were recruited
at community research sites within each target
community using targeted and respondent-
driven sampling methods. The first study was
an observational cohort study that targeted
IDUs between 18 and 35 years of age and
the second was an observational cross-
sectional study (Urban Resource Center
Cross-Sectional Survey) conducted among
IDUs aged 18 years and older. The final sam-
ple (combined across each study) included
278 IDUs in the preintervention period
(intervention=134; comparison=144) and
450 IDUs in the postintervention period
(intervention=239; comparison=211). Be-
cause these studies ran concurrently and
were conducted by the same research staff,
participants were allowed to participate in
only 1 of the 2 studies.
Data Collection
Surveys were conducted pre- and postinter-
vention for each population in the interven-
tion and the comparison communities. An
anonymous random-digit-dial telephone sur-
vey was conducted among community resi-
dents preintervention (February 2002) and
postintervention (July 2003). In addition to
demographics, respondents were asked about
approval or disapproval of drug use, and the
effect of ESAP on street-discarded syringes,
crime, drug use, and the spread of HIV. Sur-
veys lasted approximately 25 minutes and
were administered in English and Spanish.
Spanish-language surveys had previously been
back-translated for verification of consistency.
Pharmacists also participated in anony-
mous, cross-sectional surveys regarding their
opinions and attitudes about ESAP both pre-
intervention (April 2002) and postinterven-
tion (August 2003). In addition to individual
pharmacist demographics, pharmacists were
asked about their support for ESAP and their
opinions of ESAP’s effect on street-discarded
syringes, drug abuse, and HIV transmission.
Data collected among IDUs from both
observational studies focused on social and
behavioral risk factors for HIV, hepatitis C
virus, and hepatitis B virus infections. In addi-
tion to existing sociodemographic data, new
ESAP-related variables were added to both
surveys and included knowledge about ESAP,
source of pharmacy syringes, syringe sharing,
and syringe reuse. IDUs surveyed from Janu-
ary 1, 2001, to June 31, 2002, comprised the
preintervention sample and those surveyed
from July 1, 2002, to September 1, 2004,
comprised the postintervention sample.
Intervention Activities
The Harlem ESAP Intervention Project
spanned between July 1, 2002, and June 30,
2003, and was fully designed and imple-
mented by the Intervention Work Group. Ac-
tivities targeting community members in-
cluded visits to IDU-servicing community-
based organizations and training programs
conducted at these organizations, presenta-
tions to Harlem community boards, participa-
tion in health fairs and harm reduction meet-
ings, and an ESAP community forum at a
local church. Pamphlets were distributed and
posters were hung in community centers, hair
salons, barbershops, and bodegas.
All ESAP-registered and non-ESAP-
registered pharmacists in the intervention
community were visited and provided with
ESAP information and registration assistance.
They were also invited to a pharmacist and
pharmacy clerk training workshop. Each reg-
istered pharmacy received pharmacy-tailored
ESAP posters, pamphlets, ESAP guides, free
safe syringe-disposal containers (Fitpacks),
and regular program progress updates.
Intervention activities for IDUs included ed-
ucation about ESAP during HIV pre- and
posttest counseling, small group training ses-
sions regarding ESAP and safe syringe-
disposal practices, and ESAP stickers and
posters posted in communities where there
was high drug use. The New York Academy of
Medicine and other IDU-servicing community-
based organizations conducted 1-on-1 and
small group outreach to IDUs by disseminat-
ing ESAP pamphlets, which included a list and
map of all registered pharmacies in Harlem.
All ESAP educational materials included a
toll-free telephone number (1-866-SAFE-
SHOT) for a service that provided 24-hour in-
formation about ESAP, safe injection, syringe
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TABLE 1—Intervention Outreach Activities, by Target Population: Harlem, New York City, NY,
2002–2003
Activity Category Communitya Pharmacyb IDU
1-on-1 education 90 visits to IDU-servicing 128 visits 60 counseling sessions
CBOs
Workshops/small groups/ 1 community forum 2 pharmacist forums/ 16 groups attended 
trainings 3 CBO trainings trainingsc 3 sessions
Presentations and community 5 health fairs 3 ESAP stickering 
events 2 community board campaignsd
meetings 84 outreach eventse
2 harm/risk reduction 
meetings
Materials disseminated 1485 posters 95 pharmacy guides 2000 Fitpacksf
11 400 pamphlets 94 posters 5350 pamphlets
510 stickers 586 Fitpacksf 750 stickers
60 Fitpacksf
Note. IDU = injection drug user; CBO = community-based organization; ESAP = Expanded Syringe Access Demonstration
Program.
aNinety CBOs involved in the East/Central Harlem area community.
bUnless otherwise noted, 45 pharmacies were involved.
cAttended by 10 pharmacists.
d Outreach teams posted ESAP infomation stickers on community billboards across Harlem.
e ESAP information tables set up in high-traffic areas staffed by 2 outreach workers.
f Small black syringe-disposal containers that were preassembled and included instructions for use and harm reduction
information. Outreach workers distributed them at pharmacies, syringe exchange programs, community-based organizations.
disposal, and legal matters to IDUs and phar-
macists and staffed during regular business
hours and voice-prompted after business hours.
Data Analysis
Intervention activity materials were tabu-
lated by population and activity category. Chi-
square tests were used to compare pre- and
postintervention periods for community resi-
dent, pharmacist, and IDU cross-sectional
samples. In addition, pharmacy use reported
by IDUs during the pre- and postintervention
periods was stratified by race/ethnicity to de-
termine the effect of the intervention on
Black and Hispanic IDUs. P values < .05 were
used to help determine significant differences
for all group comparisons.
RESULTS
Intervention Activities
Table 1 presents the intervention activities
implemented at each targeted population
level. At the community level, there were 90
contacts with community-based organizations,
which included 4 community-based organiza-
tion training sessions or forums, 9 health fairs
or community meetings, and 50 1-on-1 visits
(3 visits or contacts with each community-
based organization on average). This resulted
in the distribution of 11400 ESAP pamphlets,
1485 ESAP posters, 510 ESAP stickers, and
60 Fitpacks. With regard to pharmacies, there
were 128 1-on-1 visits (3 visits to each phar-
macy on average), and 2 pharmacist training
sessions or forums that resulted in the distri-
bution of 95 ESAP pharmacy guides, 94
ESAP posters, and 586 Fitpacks. Finally, 60
1-on-1 counseling sessions, 16 focus groups,
and 87 IDU-targeted outreach events were
conducted. A total of 5350 ESAP pamphlets,
750 ESAP stickers (posted on billboards, con-
struction scaffolding, and vacant buildings)
and 2000 Fitpacks were distributed.
Community Members
Table 2 shows pre- and postintervention
awareness and perceptions of ESAP among
Harlem (intervention) and South Bronx (com-
parison) community residents. There were no
sociodemographic differences in pre- and
postintervention samples in the intervention
community or the comparison community
with respect to age, gender, and education.
Black and Hispanic residents were the major-
ity in both communities. However, there were
fewer Black (48%) and more Hispanic resi-
dents (44%) in the postintervention sample
than in the preintervention sample (54% and
36%, respectively; P<.03). Most residents
from both communities were unaware of non-
prescription syringe sales at pharmacies.
However, there was a significant increase in
ESAP awareness postintervention (14%) com-
pared with preintervention (6%; P<.01) in
the intervention community with no change
in the comparison community.
In the intervention community, a signifi-
cantly smaller proportion of the residents post-
intervention felt that street-discarded syringes
would increase (57%), and a larger proportion
felt there would be no effect (20%) compared
with preintervention perceptions (68% and
15%, respectively; P<.01). In the comparison
community, those who felt ESAP would have
no effect on street-discarded syringes de-
creased during the postintervention period
(8%) compared with the preintervention pe-
riod (16%; P<.02). Within the intervention
community, there were no differences in the
opinions of ESAP’s effect on illegal drug use
when comparing pre- and poststudy samples.
However, there was a slightly larger propor-
tion of residents in the comparison community
who felt illegal drug use would increase
(74%), and a smaller proportion who felt
there would be a decrease (2%) postinterven-
tion compared with preintervention (72% and
7%, respectively; P<.04). Finally, there was
no difference in opinion about ESAP’s effect
on the spread of HIV in the intervention com-
munity. However, in the comparison commu-
nity there was a significantly larger proportion
of residents who felt HIV would increase
(63%), and a smaller proportion who felt HIV
would decrease (22%) postintervention com-
pared with preintervention (43% and 40%,
respectively; P<.01).
Pharmacists
Attitudes and perceptions of ESAP-
registered pharmacists about nonprescription
syringe sales to IDUs, both pre- and post-
intervention, are reported in Table 3. There
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TABLE 2—Pre- and Postintervention Comparison of Demographic Characteristics and
Perceptions of ESAP among Community Residents of Harlem (n=999) and South Bronx
(n=497): New York City, NY, 2002–2003
Harlem (Intervention) South Bronx (Comparison)
Preintervention Postintervention Preintervention Postintervention 
(n = 494) (n = 505) P (n = 248) (n = 249) P
Mean age, y 42.1, 16.4 40.8, 15.9 <.21 39.3, 16.4 40.1, 15.4 <.60
Gender <.58 <.35
Men no. (%) 217 (47) 221 (45) 108 (46) 108 (50)
Women, no. (%) 277 (53) 284 (55) 140 (54) 141 (50)
Race/ethnicity <.03 <.11
Black, no. (%) 267 (54) 254 (48) 74 (27) 73 (26)
White, no. (%) 37 (7) 21 (4) 5 (1) 9 (3)
Hispanic, no. (%) 159 (36) 186 (44) 154 (67) 158 (70)
Asian, no. (%) 6 (1) 8 (2) 4 (2) 1 (0)
Other, no. (%) 10 (2) 16 (3) 7 (3) 3 (1)
Education <.46 <.21
Less than high school degree, 93 (21) 98 (23) 80 (33) 78 (33)
no. (%)
High school graduate, no. (%) 137 (29) 134 (27) 74 (28) 71 (30)
Some college, no. (%) 106 (22) 119 (25) 56 (31) 45 (18)
College graduate or more, no. (%) 144 (29) 142 (26) 35 (14) 51 (19)
Aware of ESAP <.01* <.18
Yes, no. (%) 36 (6) 74 (14) 16 (6) 26 (9)
No, no. (%) 457 (94) 420 (84) 231 (94) 220 (90)
Not sure, no. (%) 1 (0) 11 (2) 1 (0) 3 (1)
Effect of ESAP on street-discarded <.01 <.02
syringes
Increase, no. (%) 324 (68) 289 (57) 170 (71) 179 (74)
Decrease, no. (%) 48 (10) 53 (12) 21 (8) 20 (7)
No effect, no. (%) 80 (15) 101 (20) 39 (16) 23 (8)
Not sure, no. (%) 38 (7) 60 (12) 17 (5) 27 (10)
Effect of ESAP on illegal drug use <.51 <.04
Increase, no. (%) 277 (61) 280 (57) 175 (72) 177 (74)
Decrease, no. (%) 35 (7) 26 (6) 16 (7) 7 (2)
No effect, no. (%) 151 (27) 166 (31) 45 (18) 52 (18)
Not sure, no. (%) 26 (4) 31 (6) 11 (3) 13 (6)
Effect of ESAP on spread of HIV/AIDS <.60 <.01*
Increase, no. (%) 178 (40) 198 (43) 100 (43) 149 (63)
Decrease, no. (%) 202 (38) 189 (35) 100 (40) 57 (22)
No effect, no. (%) 78 (16) 75 (15) 31 (12) 20 (9)
Not sure, no. (%) 32 (6) 42 (8) 16 (6) 23 (6)
Note. ESAP = Expanded Syringe Access Demonstration Program. We used t tests for continuous variables and χ2 tests for
categorical variables. Preintervention data were collected February 2002; postintervention data were collected July 2003.
*P < .001.
were no differences in the pre- and post-
intervention pharmacist samples with respect
to gender and pharmacy type (chain vs in-
dependent). However, there were signifi-
cantly more Black (26%), and fewer White
pharmacists (17%) sampled postintervention
than preintervention (14% and 32%, respec-
tively; P<.01) in the intervention community.
There were significantly more Whites (26%)
and fewer Middle Eastern pharmacists (3%)
sampled postintervention than preinterven-
tion (20% and 38%, respectively; P<.02) in
the comparison community. A smaller propor-
tion did not support ESAP (27%), and a
larger proportion reported they were un-
decided (23%) postintervention than preinter-
vention (41% and 0%, respectively; P<.06)
in the intervention community. This differ-
ence was only marginally significant. In the
comparison community, there was a signifi-
cantly larger proportion that did not support
ESAP (63%) and fewer who supported ESAP
(34%) postintervention than preintervention
(39% and 61%, respectively; P<.05). The
majority of registered pharmacists surveyed
reported selling syringes during both time
periods for each community.
In the intervention community, significantly
fewer pharmacists felt there would be an in-
crease in street-discarded syringes (17%) and
more were undecided about the effect of
ESAP on street-discarded syringes (26%)
postintervention compared with preinterven-
tion (43% and 4%, respectively; P<.05);
there were no differences in the comparison
community. There were no significant differ-
ences in pharmacists’ opinions on whether
ESAP would increase drug use in either com-
munity pre- and postintervention. Most phar-
macists agreed that ESAP would reduce HIV
transmission in both communities; however,
fewer pharmacists agreed postintervention
(75%) than preintervention (91%; P<.08) in
the comparison community.
Injection Drug Users
Table 4 illustrates injection practices pre- and
postintervention among IDUs in the interven-
tion and comparison communities. In the inter-
vention community, the mean age of IDUs was
significantly younger during the postinterven-
tion period (36 years) compared with preinter-
vention (39 years; P<.01). However, in the
comparison community, mean age did not dif-
fer by period. In both communities, there was a
significant increase in the proportion of men
surveyed when comparing pre- and postinter-
vention periods. There tended to be more
Hispanic (66%) and White (18%) and fewer
Black IDUs (16%) in the intervention commu-
nity postintervention than preintervention
(49%, 8%, and 43%, respectively; P<.01). A
similar trend was observed in the comparison
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TABLE 3—Pre- and Postintervention Comparison of Demographic Characteristics and
Perceptions of ESAP among ESAP-Registered Pharmacists in Harlem (n=51) and South
Bronx and Brooklyn (n=80): New York City, NY, 2002–2003
Harlem (Intervention) Brooklyn and S. Bronx (Comparison)
Preintervention Postintervention Preintervention Postintervention
(n = 24) (n = 27) P (n = 47) (n = 33) P
Gender <.58 >.99
Men, no. (%) 17 (71) 21 (78) 41 (87) 29 (88)
Women, no. (%) 7 (29) 6 (22) 6 (13) 4 (12)
Race/ethnicity <.01 <.02
Black, no. (%) 3 (14) 6 (26) 3 (7) 2 (6)
White, no. (%) 7 (32) 4 (17) 9 (20) 8 (26)
Hispanic, no. (%) 7 (32) 0 (0) 2 (4) 3 (10)
Asian, no. (%) 2 (9) 9 (39) 14 (31) 17 (55)
Middle Eastern, no. (%) 3 (14) 4 (17) 17 (38) 1 (3)
Pharmacy type <.64 <.90
Independent, no. (%) 15 (65) 20 (71) 39 (83) 27 (82)
Chain or franchise, no. (%) 8 (35) 8 (29) 8 (17) 6 (18)
Have sold nonprescription syringes <.13 <.25
(ESAP-registered only)
No, no. (%) 3 (23) 1 (5) 5 (24) 2 (20)
Yes, no. (%) 10 (77) 19 (95) 16 (76) 8 (80)
Support nonprescription syringe <.06 <.05
sales to IDUs
Not Support, no. (%) 9 (41) 7 (27) 18 (39) 20 (63)
Support, no. (%) 13 (59) 13 (50) 28 (61) 11 (34)
Don’t know or undecided, no. (%) 0 (0) 6 (23) 0 (0) 1 (3)
Selling syringes to IDUs will increase <.05 <.40
street-discarded syringes
Disagree, no. (%) 12 (52) 13 (57) 29 (64) 19 (79)
Agree, no. (%) 10 (43) 4 (17) 15 (33) 5 (21)
Don’t know or undecided, no. (%) 1 (4) 6 (26) 1 (2) 0 (0)
Selling syringes to IDUs will <.31 <.64
increase drug use
Disagree, no. (%) 14 (67) 16 (62) 30 (64) 17 (53)
Agree, no. (%) 6 (29) 5 (19) 15 (32) 13 (41)
Don’t know or undecided, no. (%) 1 (5) 5 (19) 2 (4) 2 (6)
Selling syringes to IDUs will <.51 <.08
decrease HIV transmission
Disagree, no. (%) 2 (8) 1 (4) 3 (7) 3 (9)
Agree, no. (%) 22 (92) 25 (93) 42 (91) 24 (75)
Don’t know or undecided, no. (%) 0 (0) 1 (4) 1 (2) 5 (16)
Note. ESAP = Expanded Syringe Access Demonstration Program. We used t tests for continuous variables and χ2 tests for
categorical variables. Preintervention data were collected April 2002; postintervention data were collected August 2003.
community except that there were fewer White
IDUs in the postintervention than the preinter-
vention period, and fewer Black IDUs overall.
More IDUs were aware of the legality of
buying syringes in pharmacies without a
prescription in both the intervention commu-
nity (58%) and the comparison community
(45%) postintervention than preintervention
(42%, P<.01; 21%, P<.01, respectively). In
the intervention community, only about half
of IDUs during these periods knew it was
legal to carry syringes, and significantly fewer
in the comparison community had knowledge
of legal syringe possession postintervention
(37%) compared with preintervention (52%,
P<.01). Even though there were significantly
more IDUs who reported using a pharmacy
as a syringe source in both the intervention
and comparison communities post- versus
preintervention (32% vs 13%, P<.02; and
27% vs 12%, P<.04; respectively), in the in-
tervention community a smaller proportion of
IDUs reported injecting with a previously
used syringe (16%) postintervention com-
pared with preintervention (26%; P<.03);
whereas there was no significant difference in
the comparison community when comparing
over the same time period (26% vs 20%;
P<.37).
To further examine the effect of the inter-
vention on IDUs by race/ethnicity, stratified
analysis revealed that Black IDUs in the inter-
vention community were significantly more
likely to use pharmacies postintervention
(22%) than preintervention (5%; P<.02), al-
though there was no significant difference in
pharmacy use among Black IDUs in the com-
parison community postintervention (11%)
than preintervention (8%; P >.99). There was
also a significant increase among Hispanic
IDUs in both intervention and comparison
communities when comparing postinterven-
tion and preintervention periods (34% vs
15%, P<.005; and 29% vs 13%, P<.001,
respectively).
DISCUSSION
A multilevel intervention that was imple-
mented by a community and academic part-
nership to create a more socially receptive
environment appears to have contributed to
positive behavior change in the intervention
community, and either no change of opinions
or increased negative opinions in the com-
parison community. Specifically, there was an
increase in positive opinions and a decrease
in negative opinions and attitudes toward
pharmacy syringe sales to IDUs among com-
munity residents and pharmacists in the
intervention community. Also, negative atti-
tudes shifted to an “undecided” viewpoint
in the intervention community only. Thus, in
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TABLE 4—Pre- and Postintervention Comparison of Demographic Characteristics and
Injection Practices Among IDUs in Harlem (n=509) and South Bronx (n=444): New York
City, NY, 2001–2004
Harlem (Intervention) South Bronx (Comparison)
Preintervention Postintervention Preintervention Postintervention 
(n = 134) (n = 239) P (n = 144) (n = 211) P
Mean age, y (SD) 39.1 (8.9) 36.2 (8.3) <.01 37.2 (9.2) 36.3 (7.8) <.33
Gender <.05 <.01
Men, no. (%) 88 (67) 184 (78) 98 (69) 167 (80)
Women, no. (%) 44 (33) 53 (22) 44 (31) 43 (20)
Race/ethnicity <.01* <.01*
Hispanic, no. (%) 65 (49) 158 (66) 110 (76) 191 (91)
Black, no. (%) 58 (43) 37 (16) 25 (17) 18 (9)
White/other, no. (%) 11 (8) 43 (18) 9 (6) 2 (1)
Knew it was legal to buy syringes at <.01 <.01*
pharmacies without a prescription
Yes, no. (%) 55 (42) 138 (58) 29 (21) 95 (45)
No, no. (%) 77 (58) 101 (42) 111 (79) 115 (55)
Knew it was legal to carry syringes <.72 <.01
Yes, no. (%) 74 (47) 78 (50) 83 (52) 78 (37)
No, no. (%) 66 (53) 132 (50) 78 (48) 132 (63)
New or previously used syringe at <.03 <.37
last injection
New, no. (%) 198 (74) 195 (84) 106 (80) 157 (75)
Used, no. (%) 34 (26) 38 (16) 27 (20) 51 (26)
Pharmacy use in past 6 months <.01** <.01*
Yes, no. (%) 18 (13) 77 (32) 17 (12) 57 (27)
No, no. (%) 116 (87) 162 (68) 127 (88) 154 (73)
Note: We used t tests for continuous variables and χ2 tests for categorical variables. Preintervention data were collected
January 2001–June 2002; postintervention data were collected July 2002–September 2004.
*P < .001.
some cases negative perceptions might not
have been completely dispelled, but pharma-
cists’ previous negative opinions might have
been shifted toward a more positive opinion
of ESAP. Finally, although there was an in-
crease in pharmacy use among IDUs in both
communities, there was a significant decrease
in syringe reuse, as well as a significant in-
crease in pharmacy use among Black IDUs
in the intervention community when pre-
and postintervention periods were compared.
Elements of multilevel community interven-
tions (or structural interventions) with multi-
level pre- and postintervention evaluation and
comparison communities have been described
in the literature.21 Community and academic
partnerships have also been described22,23 and
used in community-based participatory re-
search to address a variety of health-related
problems,20,24 but to date most partnerships
have been evaluated on process rather than
outcome. Although multilevel interventions
(individual, provider, community) have been
considered important to the research commu-
nity,25–28 they have been designed and led by
research professionals.25,26 Examples include
nonrandomized pre- and postintervention de-
signs for disease prevention projects, which in
general have the closest similarity to the results
reported here. For instance, HIV intervention
programs for drug users have used community
outreach to achieve reductions in individual-
level risk behaviors,29 but generally the evalua-
tions have been conducted using individual
pre- and postintervention questionnaires. Drug
abuse treatment has been evaluated at the indi-
vidual level by comparing in-treatment with
out-of-treatment populations,30 but follow-up
typically has been limited to in-treatment
modalities. Using community ecological de-
signs, injection risk behaviors of syringe ex-
change program participants and nonpartici-
pants have been evaluated before the start of
the syringe program rather than after.1,31 More
recently, Connecticut policy makers changed a
law to allow nonprescription syringe sales in
pharmacies, and separate evaluations of drug
users and pharmacists show that program use
and changes in risk behavior occurred after the
law was changed.32,33 Data from Connecticut
have also been compared with data from other
states that had more restricted syringe access.34
These latter studies are what stimulated the
law change in New York State as well as the
multilevel intervention program we described.
Limitations
Although our findings provide solid evi-
dence of an intervention effect, there were a
few limitations in the analytic approach. The
use of cross-sectional data to evaluate the ef-
fect of a community-based multilevel interven-
tion on individual behavior may be subject to
some sources of bias and may be less sensitive
to the effect of recent behavior change than
prospective studies. However, the pre- and
postintervention cross-sectional analytic
method chosen here is a prudent and more
cost-efficient first approach to determine the
effect of a multilevel design. Separate cross-
sectional evaluations of each level may also be
limited in that they do not provide estimates
of the independent effects of each factor ex-
amined (i.e., community-level and pharmacy-
level factors) on IDU behavior. If the sample
size permitted, such information would be sig-
nificant from a public health and research per-
spective by identifying the role of the social
environment, which in turn lends further sup-
port for a multilevel intervention design. How-
ever, separate analyses have merit and pro-
vide firm evidence of the intervention effect.
As with any community intervention, there
was the potential for a contamination effect;
our finding of increased pharmacy use in
both communities may be an example of this
effect. However, in the comparison commu-
nity there was a decrease in IDU knowledge
of the legality of syringe possession despite
an increase in pharmacy use. A possible ex-
planation for these contradictory findings in
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the comparison community is that some
ESAP information may have spread more ef-
ficiently among drug-use networks, such as
which pharmacists are selling syringes, as op-
posed to more detailed information, such as
when syringes are legal and illegal to possess.
We must also note the possibility of selec-
tion bias which may partially explain the
changes that we have observed. Specifically,
pre- and postintervention IDU samples dif-
fered with respect to age, race, and gender,
which could have been independently associ-
ated with pharmacy use. There have been no
differences observed in pharmacy use by gen-
der, although older IDUs and minorities have
been significantly less likely to use pharma-
cies in previous reports.12–14,35 The fact that
the postintervention sample tended to be
younger and that there was a larger propor-
tion of White IDUs in the intervention com-
munity may partially explain the increase in
pharmacy use. Yet some of the demographic
differences provide notable evidence of an in-
tervention effect. For example, the increased
proportion of Hispanic and Latino IDUs cou-
pled with the increased pharmacy use among
this group in both communities may suggest
more of a contamination effect, which in fact
is a positive effect from a public health per-
spective given their minimal use before the
start of this project.11,14,15,35
The pharmacy participation rates may also
indicate the possibility of selection bias; for
example, those that participated may have
been more likely to support ESAP. To assess
this potential bias, we compared the partici-
pants to the nonparticipants with regard to
pharmacy type (chain vs nonchain) because
previous data indicated nonchain pharmacies
to be more supportive of ESAP. For pre- and
postintervention samples in each community,
there were no differences with respect to the
proportion of nonchain pharmacies, which
provides some evidence of balance with re-
spect to ESAP supporters. We also noted
race/ethnicity differences in pre- and postin-
tervention pharmacy samples in both commu-
nities. However, previous research has not
found an association between pharmacists’
race/ethnicity and ESAP support.36
Finally, the use of community-based par-
ticipatory research could also be a drawback
for others who want to conduct similar
interventions, because it can take a year or
more to develop trusting and productive rela-
tionships between academic centers and
community-based organizations20; thus, in
order for this approach to work with urgent
public heath problems, a viable partnership
needs to be in place. The evaluation pre-
sented here suggests that establishing this
type of partnership can be a worthwhile in-
vestment for future programs implemented in
this community.
Conclusions
Although structural or multilevel interven-
tion approaches have been suggested for a
variety of public health problems—including
HIV prevention as early as the year 200021—
this is the first community-based multilevel in-
tervention, to our knowledge, that has been
evaluated in the HIV-prevention arena with
pre- and postintervention measures for com-
munity, provider, and individual populations.
The findings presented here have important
implications for both research and practice.
Multilevel interventions, which take into ac-
count critical elements of the social environ-
ment that may hinder positive behavior
change, should be considered a viable disease
prevention strategy. Without addressing multi-
ple competing social forces, a public health
program such as ESAP will be minimally
used, particularly by Black and Hispanic drug
users who historically have been mistreated.
We have shown here that this intervention
strategy may be an efficient and effective
strategy to increase the likelihood of individ-
ual behavior change and, consequently, a
strategy to help reduce racial disparities in a
variety of health outcomes.
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